2. Search Result
Search Result
Results for "

sympathetic

" in MedChemExpress (MCE) Product Catalog:

40

Inhibitors & Agonists

11

Peptides

2

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0569
    Hexamethonium Bromide
    3 Publications Verification

    		 nAChR Apoptosis Cardiovascular Disease Neurological Disease
    Hexamethonium Bromide is a non-selective ganglionic nicotinic-receptor antagonist (nAChR) antagonist, with mixed competitive and noncompetitive activity. Hexamethonium Bromide has anti-hypertensive activity. Hexamethonium Bromide attenuates sympathetic activity and blood pressure in spontaneously hypertensive animal models .
    Hexamethonium Bromide
  • HY-P3419
    PAMP-12 (unmodified)

    		Mas-related G-protein-coupled Receptor (MRGPR) Cardiovascular Disease
    PAMP-12 (unmodified) is a potent MRGPRX2 (MrgX2) agonist (EC50=20-50 nM). PAMP-12 (unmodified) is an endogenous peptide that elicit hypotension through inhibiting catecholamine secretion from sympathetic nerve endings and adrenal chromaffin cells .
    PAMP-12 (unmodified)
  • HY-107648
    McN-A-343
    2 Publications Verification

    		 mAChR Inflammation/Immunology
    McN-A-343 is a selective M1 muscarinic agonist that stimulates muscarinic transmission in sympathetic ganglia. McN-A-343 reduces inflammation and oxidative stress in an experimental model of ulcerative colitis . McN-A-343 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    McN-A-343
  • HY-B1098
    Hydroxyamphetamine

    4-Hydroxyamphetamine

    		 Others Neurological Disease
    Hydroxyamphetamine (4-Hydroxyamphetamine) is a sympathomimetic agent, stimulates the sympathetic nervous system. Hydroxyamphetamine can be used in eye drops to dilate the pupil .
    Hydroxyamphetamine
  • HY-B1660
    Guanadrel sulfate

    		Others Cardiovascular Disease
    Guanadrel (sulfate) is an orally active, potent and postganglionic sympathetic inhibitor. Guanadrel (sulfate) lowers blood pressure by reducing systemic vascular resistance with little effect on cardiac output. Guanadrel (sulfate) is promising for research of hypertension .
    Guanadrel sulfate
  • HY-106512
    Cianergoline

    		Prostaglandin Receptor Others
    Cianergoline is a ergoline derivative with the activity of reducing intraocular pressure (IOP). Its primary regulatory mechanism involves the inhibition of sympathetic nervous function, achieved through actions on both prejunctional (DA2) and postjunctional (α1) adrenergic receptors. Cianergoline can be used for research in the field of glaucoma .
    Cianergoline
  • HY-121313
    Embusartan

    BAY 10-6734

    		 Angiotensin Receptor Neurological Disease Endocrinology
    Embusartan (BAY 10-6734) is a brain-penetrant and effective AT1 receptor blocker. Embusartan inhibits Ang II binding to brain AT1 receptors in the nuclei of central nervous system (CNS) inside due to high lipophilic character. Embusartan is promising for research of sympathetic hyperactivity and hypertension .
    Embusartan
  • HY-19037
    SM-2470

    		Adrenergic Receptor Neurological Disease Metabolic Disease
    SM-2470 is a potent α1-adrenoceptor antagonist, has sympathetic nerve activity in anesthetized rats . SM-2470 is an antihypertensive agent. SM-2470 exhibits hypocholesterolaemic effect by the inhibition of cholesterol absorption related to the reduction of cholesterol solubilization .
    SM-2470
  • HY-106447
    Losulazine

    		Others Metabolic Disease
    Losulazine is an antihypertensive agent acting by a sympatholytic mechanism. Losulazine's hypotensive activity depends on the presence of an intact, functional sympathetic nervous system .
    Losulazine
  • HY-B1098B
    Hydroxyamphetamine hydrochloride

    4-Hydroxyamphetamine hydrochloride

    		 Others Neurological Disease
    Hydroxyamphetamine (4-Hydroxyamphetamine) hydrochloride is a sympathomimetic agent, stimulates the sympathetic nervous system. Hydroxyamphetamine hydrochloride can be used in eye drops to dilate the pupil .
    Hydroxyamphetamine hydrochloride
  • HY-B1251
    Guanethidine

    		Adrenergic Receptor Neurological Disease
    Guanethidine sulphate was synthesized in 1959. Guanethidine is thought to lowing blood pressure by interfering with the metabolism of chemical transmitter substances in post-ganglionic sympathetic nerve fibres.
    Guanethidine
  • HY-119750
    Budralazine

    		Others Cardiovascular Disease
    Budralazine is a vasodilator, which dilates the vascular smooth muscle and exhibits hypotensive efficacy. Budralazine inhibits the central sympathetic nerve and exhibits an anti-tachycardic effect .
    Budralazine
  • HY-B1098A
    Hydroxyamphetamine hydrobromide

    4-Hydroxyamphetamine hydrobromide

    		 Others Neurological Disease
    Hydroxyamphetamine (4-Hydroxyamphetamine) hydrobromide is a sympathomimetic agent, stimulates the sympathetic nervous system. Hydroxyamphetamine hydrobromide can be used in eye drops to dilate the pupil .
    Hydroxyamphetamine hydrobromide
  • HY-P1817
    PACAP-38 (16-38), human, mouse, rat

    		PACAP Receptor Neurological Disease
    PACAP-38 (16-38), human, mouse, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production . PACAP is a potent activator of cAMP formation .
    PACAP-38 (16-38), human, mouse, rat
  • HY-106832
    Vatanidipine

    Watanidipine; AE0047 free base

    		 Calcium Channel Cardiovascular Disease Neurological Disease
    Vatanidipine (Watanidipine) is an orally active dihydropyridine (DHP)-type calcium channel blocker and a useful antihypertensive agent. Vatanidipine shows vasodilatory effects and also suppresses noradrenaline release from sympathetic nerve endings .
    Vatanidipine
  • HY-106832A
    Vatanidipine hydrochloride

    Watanidipine hydrochloride; AE0047

    		 Calcium Channel Cardiovascular Disease Neurological Disease
    Vatanidipine (Watanidipine) hydrochloride is an orally active dihydropyridine (DHP)-type calcium channel blocker and a useful antihypertensive agent. Vatanidipine hydrochloride shows vasodilatory effects and also suppresses noradrenaline release from sympathetic nerve endings .
    Vatanidipine hydrochloride
  • HY-125347
    TA-993

    		Others Others
    TA-993 is a compound that increases limb blood flow. Its effect of increasing limb blood flow is mediated through the sympathetic nervous system, but not through adrenergic receptors, and its mechanism of action on heart rate may be different.
    TA-993
  • HY-105747A
    Guanoxyfen nitrate

    N-(3-Phenoxypropyl)guanidine nitrate; (3-Phenoxypropyl)guanidine nitrate

    		 Others Infection Neurological Disease
    Guanoxyfen (N-(3-Phenoxypropyl)guanidine) nitrate is a compound that exhibits potent inhibitory activity against the serine protease enzyme TMPRSS2, which plays a crucial role in the infectivity of coronaviruses. Guanoxyfen nitrate is also an effective inhibitor of vasoconstrictor responses to sympathetic nerve stimulation.
    Guanoxyfen nitrate
  • HY-P3419A
    PAMP-12 (unmodified) (TFA)

    		Mas-related G-protein-coupled Receptor (MRGPR) Cardiovascular Disease
    PAMP-12 (unmodified) TFA is a potent MRGPRX2 (MrgX2) agonist (EC50=20-50 nM). PAMP-12 (unmodified) is an endogenous peptide that elicit hypotension through inhibiting catecholamine secretion from sympathetic nerve endings and adrenal chromaffin cells .
    PAMP-12 (unmodified) (TFA)
  • HY-120405
    RS-12254

    		Others Others
    RS-12254 is a compound with hypotensive, diuretic and sympathostatic effects, and has the activity of regulating blood pressure, water and salt metabolism and sympathetic nerve activity. RS-12254 can lower blood pressure, reduce plasma norepinephrine levels, has diuretic and natriuretic effects, and has sympathostatic properties.
    RS-12254
  • HY-N2333
    Resiniferatoxin
    1 Publications Verification

    (+)-Resiniferatoxin

    		 TRP Channel Cardiovascular Disease
    Resiniferatoxin ((+)-Resiniferatoxin), is a selective agonist of transient receptor potential vanilloid 1 (TRPV1) receptor agonist. Resiniferatoxin can be isolated from the Euphorbia resinifera plant. Resiniferatoxin eliminates TRPV1+ primary sensory afferents and blunt cardiac sympathetic afferent reflex for a relatively long period .
    Resiniferatoxin
  • HY-167741
    Chlorisondamine

    		Others Cardiovascular Disease Neurological Disease
    Chlorisondamine is a nicotinic antagonist that acts as a ganglionic blocker and has been utilized to evaluate the neurogenic contributions to blood pressure and sympathetic vasomotor tone in animal models. Chlorisondamine has demonstrated antihypertensive properties, primarily being assessed through its effects on blood pressure, cardiac output, and heart rate in various experimental settings, particularly in mice.
    Chlorisondamine
  • HY-B1789
    Telenzepine

    		mAChR Neurological Disease
    Telenzepine is an antimuscarinic agent with Kis of 0.94 nM (M1 mAChR) and 17.8 nM (M2 mAChR) binding to muscarinic receptors. Telenzepine effectively blocks synaptic transmission promoted by muscarinic or M1 receptor agonists. Thus, Telenzepine can reduce the amplitude of extracellular slow excitatory postsynaptic potentials (EC50=38 nM) and slow inhibitory postsynaptic potentials (EC50=253 nM) .
    Telenzepine
  • HY-P10289
    Neuropeptide W-30 (rat)

    NPW30, rat

    		 Neuropeptide B/W Receptor Neurological Disease
    Neuropeptide W-30 (rat) is an important stress mediator in the central nervous system that modulates the hypothalamus-pituitary-adrenal (HPA) axis and sympathetic outflow. Neuropeptide W-30 (rat) is an endogenous ligand for the two structurally related orphan G-protein-coupled receptors (GPCRs) GPR7 and GPR8. NPW-30 activates and binds to both GPR7 and GPR8 at similar effective doses .
    Neuropeptide W-30 (rat)
  • HY-100490
    Rilmenidine

    		Imidazoline Receptor Adrenergic Receptor Apoptosis Autophagy Cardiovascular Disease Cancer
    Rilmenidine, an innovative antihypertensive agent, is an orally active, selective I1 imidazoline receptor agonist. Rilmenidine is an alpha 2-adrenoceptor agonist. Rilmenidine induces autophagy. Rilmenidine acts both centrally by reducing sympathetic overactivity and in the kidney by inhibiting the Na +/H + antiport. Rilmenidine modulates proliferation and stimulates the proapoptotic protein Bax thus inducing the perturbation of the mitochondrial pathway and apoptosis in human leukemic K562 cells .
    Rilmenidine
  • HY-100490B
    Rilmenidine phosphate

    		Imidazoline Receptor Adrenergic Receptor Apoptosis Autophagy Cardiovascular Disease Cancer
    Rilmenidine phosphate, an innovative antihypertensive agent, is an orally active, selective I1 imidazoline receptor agonist. Rilmenidine phosphate is an alpha 2-adrenoceptor agonist. Rilmenidine phosphate induces autophagy. Rilmenidine phosphate acts both centrally by reducing sympathetic overactivity and in the kidney by inhibiting the Na +/H + antiport. Rilmenidine phosphate modulates proliferation and stimulates the proapoptotic protein Bax thus inducing the perturbation of the mitochondrial pathway and apoptosis in human leukemic K562 cells .
    Rilmenidine phosphate
  • HY-P10287
    Neuropeptide W-30 (human)

    NPW30, human

    		 Neuropeptide B/W Receptor Neurological Disease
    Neuropeptide W-30 (human) is an important stress mediator in the central nervous system that modulates the hypothalamus-pituitary-adrenal (HPA) axis and sympathetic outflow. Neuropeptide W-30 (human) is an endogenous ligand for the two structurally related orphan G-protein-coupled receptors (GPCRs) GPR7 and GPR8. Neuropeptide W-30 (human) activates and binds to both GPR7 and GPR8 at similar effective doses .
    Neuropeptide W-30 (human)
  • HY-B1231
    Heptaminol hydrochloride

    RP-2831 hydrochloride

    		 Others Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Heptaminol (RP-2831) hydrochloride is a vasoconstrictor used in the study of hypotension, especially orthostatic hypotension. Heptaminol is also a skin cancer proliferation inhibitor that inhibits immune inflammation induced by the tumor promoting factor 12-O-tetradecanoylphorbol-13-acetate (TPA) in an NO-dependent manner. Heptaminol also acts as a sympathomimetic amine, exerting indirect sympathetic effects. Heptaminol is also an antagonist of catecholamine release and uptake and can increase intracellular free calcium levels .
    Heptaminol hydrochloride
  • HY-100490A
    Rilmenidine hemifumarate

    		Imidazoline Receptor Adrenergic Receptor Apoptosis Autophagy Cardiovascular Disease Cancer
    Rilmenidine hemifumarate, an innovative antihypertensive agent, is an orally active, selective I1 imidazoline receptor agonist. Rilmenidine hemifumarate is an alpha 2-adrenoceptor agonist. Rilmenidine hemifumarate induces autophagy. Rilmenidine hemifumarate acts both centrally by reducing sympathetic overactivity and in the kidney by inhibiting the Na +/H + antiport. Rilmenidine hemifumarate modulates proliferation and stimulates the proapoptotic protein Bax thus inducing the perturbation of the mitochondrial pathway and apoptosis in human leukemic K562 cells .
    Rilmenidine hemifumarate
  • HY-W263279
    (E)-Guanabenz

    (E)-Wy-8678

    		 Adrenergic Receptor Cardiovascular Disease Neurological Disease
    (E)-Guanabenz ((E)-Wy-8678) is an orally active central α2-adrenoceptor agonist. (E)-Guanabenz has antihypertensive activity, acts via stimulating central α2-adrenoceptors, and reducing net sympathetic outflow into the periphery. (E)-Guanabenz also directly binds to and inhibits GADD34, and has neuroprotective activity. (E)-Guanabenz can be used for researching hypertension and Parkinson disease .
    (E)-Guanabenz
  • HY-100490S
    Rilmenidine-d4

    		Isotope-Labeled Compounds Imidazoline Receptor Adrenergic Receptor Apoptosis Autophagy Cardiovascular Disease Cancer
    Rilmenidine-d4 is the deuterium labeled Rilmenidine. Rilmenidine, an innovative antihypertensive agent, is an orally active, selective I1 imidazoline receptor agonist. Rilmenidine is an alpha 2-adrenoceptor agonist. Rilmenidine induces autophagy. Rilmenidine acts both centrally by reducing sympathetic overactivity and in the kidney by inhibiting the Na+/H+ antiport. Rilmenidine modulates proliferation and stimulates the proapoptotic protein Bax thus inducing the perturbation of the mitochondrial pathway and apoptosis in human leukemic K562 cells[1][2][3].
    Rilmenidine-d4
  • HY-B1435A
    Moxisylyte

    Thymoxamine

    		 Others Neurological Disease
    Moxisylyte (Thymoxamine) is an alpha 1-selective antagonist with activity that improves bladder emptying. Moxisylyte is used to suppress urinary difficulties in patients with multiple system atrophy (MSA) by blocking alpha 1-adrenergic receptors to reduce the amount of residual urine after urination. Moxisylyte is also used to suppress erectile dysfunction and can improve blood circulation problems caused by Raynaud's syndrome in the short term. In addition, Moxisylyte can be applied topically to the eye to reverse the mydriasis caused by phenylephrine and other sympathetic stimulants .
    Moxisylyte
  • HY-B1231R
    Heptaminol hydrochloride (Standard)

    		Others Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Heptaminol (hydrochloride) (Standard) is the analytical standard of Heptaminol (hydrochloride). This product is intended for research and analytical applications. Heptaminol (RP-2831) hydrochloride is a vasoconstrictor used in the study of hypotension, especially orthostatic hypotension. Heptaminol is also a skin cancer proliferation inhibitor that inhibits immune inflammation induced by the tumor promoting factor 12-O-tetradecanoylphorbol-13-acetate (TPA) in an NO-dependent manner. Heptaminol also acts as a sympathomimetic amine, exerting indirect sympathetic effects. Heptaminol is also an antagonist of catecholamine release and uptake and can increase intracellular free calcium levels .
    Heptaminol hydrochloride (Standard)
  • HY-P1845
    PACAP-38 (31-38), human, mouse, rat

    		ERK EGFR Reactive Oxygen Species Calcium Channel Neurological Disease
    PACAP-38 (31-38), human, mouse, rat is a PAC1 receptor activator and increases the α-secretase activity. PACAP-38 (31-38), human, mouse, rat elevates cytosolic Ca 2+, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP-38 (31-38), human, mouse, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP-38 (31-38), human, mouse, rat can be used for neurotrophic and neuroprotective research .
    PACAP-38 (31-38), human, mouse, rat
  • HY-P1845A
    PACAP-38 (31-38), human, mouse, rat TFA

    		ERK EGFR Reactive Oxygen Species Calcium Channel Neurological Disease
    PACAP-38 (31-38), human, mouse, rat TFA is a PAC1 receptor activator and increases the α-secretase activity. PACAP-38 (31-38), human, mouse, rat TFA elevates cytosolic Ca 2+, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP-38 (31-38), human, mouse, rat TFA demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP-38 (31-38), human, mouse, rat TFA can be used for neurotrophic and neuroprotective research .
    PACAP-38 (31-38), human, mouse, rat TFA
  • HY-13948BS
    Angiotensin II human-13C6,15N TFA

    Angiotensin II-13C6,15N TFA; Ang II-13C6,15N TFA; DRVY(I-13C6,15N)HPF TFA

    		 Isotope-Labeled Compounds Cancer
    Angiotensin II human- 13C6, 15N TFA (Ang II- 13C6, 15N TFA) is 13C- and 15N-labeled Angiotensin II human (TFA) (HY-13948B). Angiotensin II human (Angiotensin II) TFA is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human TFA plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). Angiotensin II human TFA stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions .
    Angiotensin II human-13C6,15N TFA
  • HY-13948
    Angiotensin II human
    Maximum Cited Publications
    111 Publications Verification

    Angiotensin II; Ang II; DRVYIHPF

    		 Angiotensin Receptor Apoptosis Cardiovascular Disease Endocrinology Cancer
    Angiotensin II (Angiotensin II) is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). Angiotensin II human stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. Angiotensin II human induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. Angiotensin II human also induces apoptosis. Angiotensin II induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway .
    Angiotensin II human
  • HY-13948A
    Angiotensin II human acetate
    Maximum Cited Publications
    111 Publications Verification

    Angiotensin II acetate; Ang II acetate; DRVYIHPF acetate

    		 Angiotensin Receptor Apoptosis Cardiovascular Disease Endocrinology Cancer
    Angiotensin II human (Angiotensin II) acetate is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human acetate plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). Angiotensin II human acetate stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. Angiotensin II human acetate induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. Angiotensin II human acetate also induces apoptosis. Angiotensin II human acetate induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway .
    Angiotensin II human acetate
  • HY-13948B
    Angiotensin II human TFA
    Maximum Cited Publications
    111 Publications Verification

    Angiotensin II TFA; Ang II TFA; DRVYIHPF TFA

    		 Angiotensin Receptor Apoptosis Cardiovascular Disease Endocrinology Cancer
    Angiotensin II human (Angiotensin II) TFA is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human TFA plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). Angiotensin II human TFA stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. Angiotensin II human TFA induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. Angiotensin II human TFA also induces apoptosis. Angiotensin II human TFA induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway .
    Angiotensin II human TFA
  • HY-136625
    LY134046

    		Others Neurological Disease
    LY134046 is an inhibitor of norepinephrine N-methyltransferase (NMT). Its cardiovascular activity was studied in anesthetized spontaneously hypertensive rats (SHR). Acute intraperitoneal injection of 10 and 20 mg/kg of LY134046 caused minimal cardiovascular changes, while 40 mg/kg resulted in a sustained decrease in mean arterial blood pressure and heart rate. This hypotension and bradycardia occurred rapidly and occurred when brain NMT activity was significantly inhibited. However, norepinephrine concentrations in rat brains were not significantly reduced at the time when LY134046-induced blood pressure and heart rate effects were maximal. The acute cardiovascular activity of LY134046 was not significantly affected by pretreatment of SHR with phentolamine, propranolol, or atropine, and LY134046 reduced heart rate in suspended SHR. In addition, acute or chronic administration of LY134046 did not antagonize the vasoconstrictor responses induced by sympathetic nerve stimulation or exogenous norepinephrine. These observations suggest that LY134046 does not interact with adrenergic or cholinergic receptors and that its hypotensive and bradycardic effects do not require neurogenic tension. Chronic intraperitoneal administration of LY134046 (40 mg/kg/day) resulted in a sustained and significant inhibition of hypothalamic and brainstem NMT activity, leading to central norepinephrine depletion. During chronic treatment, norepinephrine and dopamine concentrations increased in the brainstem and hypothalamus of SHR. Despite chronic inhibition of central NMT and norepinephrine depletion, cardiovascular parameters in SHR treated groups were not significantly different from those in saline-injected controls. Chronic treatment with LY134046 did not result in tolerance to its central biochemical effects or acute cardiovascular activity. The present study does not support the idea that norepinephrine-producing neurons are involved in the central regulation of cardiovascular function, because the hypotension and bradycardia induced by acute administration of LY134046 occurred before a significant decrease in hypothalamic norepinephrine concentrations, whereas chronic inhibition of central NMT and depletion of norepinephrine resulted in minimal changes in baseline cardiovascular parameters.
    LY134046

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: